GSE226249 pirfenidone HL 2 v 6 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE226249_pirfenidone_HL_2_v_6_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE226249_pirfenidone_HL_2_v_6_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE226249_pirfenidone_HL_2_v_6_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE226249_pirfenidone_HL_2_v_6_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H3.7 histone (putative)

Gene

long intergenic non-protein coding RNA 3219

Gene

TMPO antisense RNA 1

Gene

Myb/SANT DNA binding domain containing 7

Gene

MBNL1 antisense RNA 1

Gene

ZFHX3 antisense RNA 1

Gene

long intergenic non-protein coding RNA 2535

Gene

Rho GTPase activating protein 11B

Gene

long intergenic non-protein coding RNA 1572

Gene

HAS2 antisense RNA 1

  • Gene

    H3.7 histone (putative)


  • Gene

    long intergenic non-protein coding RNA 3219


  • Gene

    TMPO antisense RNA 1


  • Gene

    Myb/SANT DNA binding domain containing 7


  • Gene

    MBNL1 antisense RNA 1


  • Gene

    ZFHX3 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2535


  • Gene

    Rho GTPase activating protein 11B


  • Gene

    long intergenic non-protein coding RNA 1572


  • Gene

    HAS2 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.